SOURCE: Cyberkinetics Neurotechnology Systems, Inc.

June 04, 2007 19:56 ET

Cyberkinetics' President and Chief Executive Officer Talks Live With MN1

FOXBOROUGH, MA--(Marketwire - June 4, 2007) - Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN) ("Cyberkinetics") announced that Timothy R. Surgenor, Cyberkinetics' President and Chief Executive Officer, will be featured live on Market News First (www.mn1.com) for an exclusive interview with Andrew Coffey on the program "Coffey Grinds." The interview is scheduled for Tuesday, June 5, 2007, at 10:30 Eastern, 9:30 Central Daylight Time.

Join Tim Surgenor to learn more about Cyberkinetics' goals, as well as its position in the stock market. Cyberkinetics anticipates launching the first commercial neurotechnology product based upon its groundbreaking Andara™ Oscillating Field Stimulator (OFS™) technology platform as early as the fourth quarter of 2007. In February 2007, Cyberkinetics submitted a Humanitarian Device Exemption (HDE) to the Food and Drug Administration (FDA) to obtain market clearance for the implantable Andara™ OFS™ (Oscillating Field Stimulator) System. If approved, Cyberkinetics' Andara™ OFS™ System would be the first commercially available neurotechnology device designed to partially restore sensation and motor function in acute spinal cord injuries by stimulating nerve repair.

About MN1.com

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE. Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: Andara™ OFS™ Therapy for acute spinal cord injury, an investigative device designed to stimulate nerve repair and restore sensation and motor function; the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement; and a pilot program in the detection and prediction of seizures due to epilepsy. Additional information is available at Cyberkinetics' website at www.cyberkineticsinc.com.

Forward-Looking Statement

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress, potential development of proprietary inventions and benefits that may be realized by certain research programs. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.

Contact Information

  • CONTACTS:
    Elizabeth A. Razee
    Manager, Corporate Communications
    508-549-9981, Ext. 109

    Market News First
    Angie Junell
    214-461-3411
    ajunell@MN1.cm